Literature DB >> 28810936

lncRNA C2dat1 Promotes Cell Proliferation, Migration, and Invasion by Targeting miR-34a-5p in Osteosarcoma Cells.

Daofu Jia1, Yanping Niu2, Dongling Li3, Zhaorui Liu4.   

Abstract

Osteosarcoma is a highly aggressive malignant bone tumor with poor prognosis. Evidence has suggested that lncRNAs are deregulated in multiple cancers. In this study, we investigated the role of the lncRNA C2dat1 on the biological functions of osteosarcoma cells. The expressions of C2dat1, miR-34a-5p, and Sirt1 in human osteosarcoma cells were altered by transfection with their specific vectors/shRNA or mimic/inhibitor. Cell viability, migration, invasion, and apoptosis were assessed posttransfection. The mRNA and protein levels of C2dat1, miR-34a-5p, and Sirt1 were detected by qRT-PCR and Western blot. The results showed that C2dat1 suppression reduced cell viability, invasion, and migration, whereas it increased cell apoptosis in OS-732 cells. The expression of miR-34a-5p was downregulated when C2dat1 was overexpressed, whereas it negatively regulated Sirt1 expression. miR-34a-5p overexpression inhibited cell viability, migration, and invasion and promoted cell apoptosis in osteosarcoma cells by downregulation of Sirt1. Furthermore, miR-34a-5p overexpression deactivated the p38/ERK/AKT and Wnt/β-catenin signaling pathways by inhibition of Sirt1.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28810936     DOI: 10.3727/096504017X15024946480113

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  19 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Long non-coding RNAs and nuclear factor-κB crosstalk in cancer and other human diseases.

Authors:  Subash C Gupta; Nikee Awasthee; Vipin Rai; Srinivas Chava; Venugopal Gunda; Kishore B Challagundla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-19       Impact factor: 10.680

Review 3.  Long Non-coding RNAs (lncRNAs), A New Target in Stroke.

Authors:  Ziyu Wang; Xiang Li; Liangliang Huang; Ge Liu; Yan Chen; Binbin Li; Xueyan Zhao; Rong Xie; Yunman Li; Weirong Fang
Journal:  Cell Mol Neurobiol       Date:  2020-08-31       Impact factor: 5.046

Review 4.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 5.  Molecular mechanism of microRNAs regulating apoptosis in osteosarcoma.

Authors:  Xueyang Cai; Wei Yin; Chao Tang; Yubao Lu; Yuqi He
Journal:  Mol Biol Rep       Date:  2022-04-26       Impact factor: 2.742

6.  [miR-34a-5p regulates viability, invasion and apoptosis of placental trophoblastic cells via modulating CDK6 and PI3K/AKT pathway].

Authors:  Qin Li; Juanxiu Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

Review 7.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

8.  Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis.

Authors:  Xuecheng Shao; Xuehui Zheng; Dan Ma; Yang Liu; Guoyan Liu
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

Review 9.  MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.

Authors:  Ammad Ahmad Farooqi; Sobia Tabassum; Aamir Ahmad
Journal:  Int J Mol Sci       Date:  2017-10-02       Impact factor: 5.923

10.  Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorigenesis via PI3K/Akt pathway.

Authors:  Guangyang Yu; Gang Liu; Dongtang Yuan; Jian Dai; Yin Cui; Xiaoming Tang
Journal:  J Bone Oncol       Date:  2018-02-13       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.